Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine

Clinica Chimica Acta

Volumn 413, Issue 15-16, 2012, Pages 1259-1264

  Metz, Thomas F ^a   Mechtler, Thomas P ^a   Merk, Michael ^b   Gottschalk, Anne ^b   Lukačin, Richard ^b   Herkner, Kurt R ^a   Kasper, David C ^a  

^a UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^b Chromsystems Instrument and Chemicals GmbH   (Germany)

Author keywords

High throughput mass spectrometry; Hydrazine; Newborn screening; Succinylacetone; Tyrosinemia type I

Indexed keywords

ACYLCARNITINE; AMINO ACID; BUTANOL; HYDRAZINE; SUCCINYLACETONE; TYROSINE;

AMINO ACID ANALYSIS; ARTICLE; BLOOD ANALYSIS; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DRIED BLOOD SPOT TESTING; FEASIBILITY STUDY; FLOW INJECTION ANALYSIS; HEALTH HAZARD; HUMAN; INBORN ERROR OF METABOLISM; INTERMETHOD COMPARISON; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL; RESIDUAL BLOOD; TANDEM MASS SPECTROMETRY;

DRIED BLOOD SPOT TESTING; HEPTANOATES; HUMANS; HYDRAZINES; INFANT, NEWBORN; MASS SPECTROMETRY; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; REAGENT KITS, DIAGNOSTIC; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TYROSINEMIAS;

EID: 84861330545     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.04.007     Document Type: Article

References (18)

1. Mitchell G.A., Grompe M., Lambert M., Tanguay R.M. Hypertyrosinemia. The Metabolic and Molecular Bases of Inherited Disease 2001, 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D.V. Valle (Eds.).
2. Allard P., Grenier A., Korson M.S., Zytkovicz T.H. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 2004, 37:1010-1015.
3. La Marca G., Malvagia S., Funghini S., et al. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program. Rapid Commun Mass Spectrom 2009, 23:3891-3893.
4. Sander J., Janzen N., Peter M., et al. Newborn screening for hepatorenal tyrosinemia: tandem mass spectrometric quantification of succinylacetone. Clin Chem 2006, 52:482-487.
5. Turgeon C., Magera M.J., Allard P., et al. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin Chem 2008, 54:657-664.
6. Chace D.H., Lim T., Hansen C.R., De Jesus V.R., Hannon W.H. Improved MS/MS analysis of succinylacetone extracted from dried blood spots when combined with amino acids and acylcarnitine butyl esters. Clin Chim Acta 2009, 407:6-9.
7. Dhillon K.S., Bhandal A.S., Aznar C.P., Lorey F.W., Neogi P. Improved tandem mass spectrometry (MS/MS) derivatized method for the detection of tyrosinemia type I, amino acids and acylcarnitine disorders using a single extraction process. Clin Chim Acta 2011, 412:873-879.
8. Kasper D.C., Ratschmann R., Metz T.F., et al. The national Austrian newborn screening program - eight years experience with mass spectrometry. past, present, and future goals. Wien Klin Wochenschr 2010, 122:607-613.
9. Watson M.S., Mann M.Y., Lloyd-Puryear M.A., Rinaldo P., Howell R.R. Newborn screening: toward a uniform screening panel and system-executive summary. Pediatrics 2006, 117:S296-S307.
10. Holme E., Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 1998, 21:507-517.
11. Masurel-Paulet A., Poggi-Bach J., Rolland M.O., et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008, 31:81-87.
12. La Marca G., Malvagia S., Pasquini E., et al. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs. Rapid Commun Mass Spectrom 2008, 22:812-818.
13. Magera M.J., Gunawardena N.D., Hahn S.H., et al. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I. Mol Genet Metab 2006, 88:16-21.
14. Matern D., Tortorelli S., Oglesbee D., Gavrilov D., Rinaldo P. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007). J Inherit Metab Dis 2007, 30:585-592.
15. Weigel J.F., Janzen N., Pfaffle R.W., Thiery J., Kiess W., Ceglarek U. Tandem mass spectrometric determination of succinylacetone in dried blood spots enables presymptomatic detection in a case of hepatorenal tyrosinaemia. J Inherit Metab Dis 2007, 30:610.
16. Al-Dirbashi O.Y., Rashed M.S., Jacob M., et al. Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS. Biomed Chromatogr 2008, 22:1181-1185.
17. Marquardt G., Currier R., McHugh D.M. Enhanced interpretation of newborn screening results without analyte cutoff values. Genet Med advance online publication February 16 2012, 10.1038/gim.2012.2.
18. McHugh D.M., Cameron C.A., Abdenur J.E., et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 2011, 13:230-254.